In Q2, Astra sustained its solid top-line momentum. Like in the past few quarters, this outperformance was again driven by higher COVID-19 business sales and solid growth in Diabetes drug Farxiga. Moreover, the recovering Oncology and much-needed green shoots in Rare Diseases were the icing on the cake. Although, profitability again came under the scanner but should improve in the coming quarters/years as the company completes its ‘growth phase’. Overall, a decent set of results and our positive ....
29 Jul 2022
Strong top-line drives another decent quarter
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Strong top-line drives another decent quarter
AstraZeneca PLC (AZN:LON) | 11,388 13437.8 1.0% | Mkt Cap: 176,540m
- Published:
29 Jul 2022 -
Author:
Amandeep Goyal | Abhishek Raval -
Pages:
5
In Q2, Astra sustained its solid top-line momentum. Like in the past few quarters, this outperformance was again driven by higher COVID-19 business sales and solid growth in Diabetes drug Farxiga. Moreover, the recovering Oncology and much-needed green shoots in Rare Diseases were the icing on the cake. Although, profitability again came under the scanner but should improve in the coming quarters/years as the company completes its ‘growth phase’. Overall, a decent set of results and our positive ....